The application prospects of honokiol in dermatology.

Yao Li, Chenglin Liang, Xiyuan Zhou
Author Information
  1. Yao Li: Institute of Dermatology and Venereology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology, Chengdu, China.
  2. Chenglin Liang: Institute of Dermatology and Venereology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology, Chengdu, China.
  3. Xiyuan Zhou: Institute of Dermatology and Venereology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology, Chengdu, China.

Abstract

honokiol is one of the natural extracts of Magnolia officinalis. It is a small molecule, lipophilic compound with extensive biological effects. It has been used in the treatment of multisystem diseases, including digestive diseases, endocrine diseases, nervous system diseases, and various tumors. This paper reviews the biological effects of honokiol on the treatment of skin diseases in recent years, including anti-microbial, anti-oxidant, anti-inflammatory, anti-tumor, anti-fibrosis, anti-allergy, photo-protection, and immunomodulation. Most current researches are focused on the effects of anti-melanoma and photo-protection. Therefore, we summarized the specific mechanisms about these two effects. On the other side of treating skin diseases, the advantages of topical drugs cannot be replaced. As a small molecule fat-soluble compound, honokiol is suitable for external use. We reviewed the advantages and disadvantages of the topical mixed cream and various improved methods. These improvements include physical and chemical penetration enhancers, drug carriers, and chemical derivatives. In conclusion, honokiol has a wide range of effects, and its topical preparation provides a safe and effective way for treating skin diseases.

Keywords

References

  1. Dermatol Ther. 2022 Aug;35(8):e15658 [PMID: 35726011]
  2. Br J Cancer. 2013 Jul 23;109(2):433-43 [PMID: 23807168]
  3. Oncotarget. 2016 Feb 16;7(7):7899-912 [PMID: 26760964]
  4. Cancer Med. 2019 Mar;8(3):1186-1196 [PMID: 30793515]
  5. Int J Radiat Biol. 2011 Jun;87(6):579-90 [PMID: 21473672]
  6. Virol Sin. 2019 Jun;34(3):315-323 [PMID: 30915606]
  7. Oncotarget. 2016 Mar 15;7(11):12857-68 [PMID: 26871475]
  8. J Microbiol Biotechnol. 2019 Apr 28;29(4):538-547 [PMID: 30939634]
  9. Am J Surg. 2012 Dec;204(6):868-73 [PMID: 23231930]
  10. Int J Mol Sci. 2021 Dec 12;22(24): [PMID: 34948151]
  11. Planta Med. 2018 Nov;84(16):1151-1164 [PMID: 29925102]
  12. Pharmacol Res. 2019 Jun;144:192-209 [PMID: 31002949]
  13. Front Pharmacol. 2018 Apr 24;9:392 [PMID: 29740318]
  14. Anticancer Res. 2010 Mar;30(3):777-83 [PMID: 20392996]
  15. Appl Microbiol Biotechnol. 2015 May;99(10):4387-96 [PMID: 25586586]
  16. Exp Biol Med (Maywood). 2011 Nov;236(11):1351-9 [PMID: 21908486]
  17. Emerg Microbes Infect. 2019;8(1):707-716 [PMID: 31119985]
  18. Carcinogenesis. 2010 Nov;31(11):2004-11 [PMID: 20823108]
  19. Biomed Pharmacother. 2021 Sep;141:111793 [PMID: 34098216]
  20. Mol Nutr Food Res. 2016 Jun;60(6):1383-95 [PMID: 27276215]
  21. Theranostics. 2019 Feb 28;9(6):1614-1633 [PMID: 31037127]
  22. AAPS PharmSciTech. 2018 Nov;19(8):3501-3511 [PMID: 30259402]
  23. Biol Pharm Bull. 1997 Sep;20(9):983-7 [PMID: 9331981]
  24. FASEB J. 2020 Oct;34(10):13284-13299 [PMID: 32813287]
  25. Clin Interv Aging. 2012;7:351-61 [PMID: 23049247]
  26. J Ethnopharmacol. 2014 Sep 29;155(3):1568-74 [PMID: 25102243]
  27. Am J Surg. 2014 Dec;208(6):995-1002; discussion 1001-2 [PMID: 25450590]
  28. J Microbiol Biotechnol. 2020 Dec 28;30(12):1835-1842 [PMID: 33263334]
  29. Plants (Basel). 2021 Nov 19;10(11): [PMID: 34834886]
  30. Int J Nanomedicine. 2021 Aug 24;16:5693-5712 [PMID: 34465990]
  31. Front Cell Dev Biol. 2020 Nov 24;8:603472 [PMID: 33330500]
  32. Planta Med. 2005 Apr;71(4):338-43 [PMID: 15856410]
  33. J Pharm Sci. 1981 Aug;70(8):951-2 [PMID: 7310672]
  34. PLoS One. 2015 Feb 24;10(2):e0117695 [PMID: 25710475]
  35. Front Pharmacol. 2017 Apr 19;8:206 [PMID: 28469575]
  36. Sci Rep. 2017 May 10;7(1):1657 [PMID: 28490739]
  37. J Pharmacol Sci. 2015 Jul;128(3):116-24 [PMID: 26220468]
  38. Oncotarget. 2016 Oct 25;7(43):69321-69336 [PMID: 27732568]
  39. J Biol Chem. 2017 Jul 14;292(28):11727-11739 [PMID: 28546431]
  40. Biomed Pharmacother. 2019 Jun;114:108777 [PMID: 30925455]
  41. Adv Exp Med Biol. 2016;928:245-265 [PMID: 27671820]
  42. Mol Carcinog. 2015 Dec;54(12):1710-21 [PMID: 25491779]
  43. PLoS One. 2017 Feb 13;12(2):e0172228 [PMID: 28192489]
  44. Biol Pharm Bull. 2007 Nov;30(11):2201-3 [PMID: 17978501]
  45. Drug Deliv. 2010 Apr;17(3):138-44 [PMID: 20175649]
  46. Biochem Pharmacol. 2008 Sep 1;76(5):589-96 [PMID: 18640101]
  47. Lett Appl Microbiol. 2010 Sep;51(3):351-7 [PMID: 20681969]
  48. Eur J Pharm Sci. 2018 Mar 1;114:189-198 [PMID: 29241737]
  49. Int J Pharm. 2013 Mar 10;445(1-2):153-62 [PMID: 23380623]
  50. Cancer Lett. 2019 Feb 1;442:113-125 [PMID: 30391358]
  51. Int J Dermatol. 2017 Jul;56(7):754-761 [PMID: 28229451]

MeSH Term

Allyl Compounds
Antioxidants
Biphenyl Compounds
Dermatology
Humans
Lignans
Phenols
Skin Diseases

Chemicals

Allyl Compounds
Antioxidants
Biphenyl Compounds
Lignans
Phenols
honokiol

Word Cloud

Created with Highcharts 10.0.0diseaseseffectshonokioltopicalskinphoto-protectionsmallmoleculecompoundbiologicaltreatmentincludingvariousanti-melanomatreatingadvantageschemicalapplicationdermatologyHonokiolonenaturalextractsMagnoliaofficinalislipophilicextensiveusedmultisystemdigestiveendocrinenervoussystemtumorspaperreviewsrecentyearsanti-microbialanti-oxidantanti-inflammatoryanti-tumoranti-fibrosisanti-allergyimmunomodulationcurrentresearchesfocusedThereforesummarizedspecificmechanismstwosidedrugsreplacedfat-solublesuitableexternaluserevieweddisadvantagesmixedcreamimprovedmethodsimprovementsincludephysicalpenetrationenhancersdrugcarriersderivativesconclusionwiderangepreparationprovidessafeeffectivewayprospects

Similar Articles

Cited By (5)